Phenoxybenzamine is a long-acting, non-selective alpha-adrenergic antagonist developed in the mid-20th century and introduced for medical use in the management of conditions associated with excessive catecholamine activity. Its history is closely linked to its effectiveness in treating pheochromocytoma, a tumor of the adrenal medulla that causes severe hypertension due to excess release of norepinephrine and epinephrine. Phenoxybenzamine works by irreversibly blocking alpha-1 and alpha-2 adrenergic receptors, leading to prolonged vasodilation and reduced blood pressure. Because of its irreversible binding, its effects last until new receptors are synthesized, making it particularly useful in preoperative management of pheochromocytoma. Over time, its use has remained specialized, mainly in endocrine and surgical settings for catecholamine-related hypertensive crises.
BRAND NAMES
Dibenzyline (most commonly known brand)
Dibenyline (used in some regions)
Phenoxybenzamine Hydrochloride (generic formulations)
MECHANISM OF ACTION
henoxybenzamine is a non-selective, irreversible alpha-adrenergic antagonist. It binds covalently to alpha-1 and alpha-2 adrenergic receptors, permanently inactivating them until new receptors are synthesized.
PHARMACOKINETICS
Absorption
Phenoxybenzamine is well absorbed after oral administration, although its bioavailability is variable due to first-pass metabolism. Onset of action is slow (within 1–2 hours), and full therapeutic effect may take several hours to develop. Food does not significantly affect absorption.
Distribution
Phenoxybenzamine is widely distributed in body tissues and is highly lipid-soluble. It is extensively bound to plasma proteins. Because of its irreversible receptor binding, its pharmacologic effects persist long after plasma levels decline.
Metabolism
The drug is metabolized in the liver into inactive metabolites. Hepatic metabolism plays an important role in its clearance, although pharmacologic effects are not dependent on plasma concentration due to irreversible receptor binding.
Elimination
Phenoxybenzamine and its metabolites are excreted primarily in the urine and to a lesser extent in bile. The duration of action is prolonged (up to 24–48 hours or more) due to irreversible alpha-receptor blockade rather than slow elimination.
PHARMACODYNAMICS
Phenoxybenzamine is a non-selective, irreversible alpha-adrenergic antagonist that blocks both alpha-1 and alpha-2 receptors. This prevents catecholamine-induced vasoconstriction, resulting in vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure. Because alpha-2 receptors are also blocked, there may be increased norepinephrine release, which can lead to reflex tachycardia. Its irreversible binding produces long-lasting effects until new receptors are synthesized.
ADMINISTRATION
Phenoxybenzamine is administered orally in capsule form. It is commonly used in the preoperative management of pheochromocytoma and occasionally in chronic catecholamine excess states. Dosage is usually started low and gradually increased to achieve adequate blood pressure control.
DOSAGE AND STRENGTH
Initial dosing is typically 10 mg once or twice daily, gradually increased every few days. Maintenance doses may range from 20–100 mg per day, depending on patient response and blood pressure control.
DRUG INTERACTIONS
Phenoxybenzamine may interact with antihypertensive drugs, leading to additive hypotension. It may also enhance the effects of vasodilators, alcohol, and CNS depressants, increasing dizziness or orthostatic hypotension. Caution is required when used with beta-blockers, which may worsen reflex tachycardia if alpha-blockade is inadequate.
FOOD INTERACTIONS
There are no major food restrictions, but alcohol should be avoided due to increased risk of hypotension and dizziness.
CONTRAINDICATIONS
Contraindications include hypersensitivity to phenoxybenzamine and conditions where significant hypotension is dangerous. It should be used cautiously in patients with coronary artery disease or severe cardiovascular instability.
SIDE EFFECTS
Common side effects include orthostatic hypotension, nasal congestion, dizziness, fatigue, and tachycardia. Some patients may experience miosis, nausea, or ejaculation disorders due to alpha-blockade.
OVER DOSAGE
Phenoxybenzamine overdose mainly results in excessive and prolonged alpha-adrenergic blockade, leading to severe hypotension. Patients may present with dizziness, fainting, blurred vision, weakness, and orthostatic collapse due to marked vasodilation. Reflex tachycardia may also occur as the body attempts to compensate for low blood pressure. In severe cases, shock, decreased organ perfusion, and cardiovascular instability can develop.
TOXICITY
Phenoxybenzamine overdose may cause severe hypotension, reflex tachycardia, dizziness, fainting, and shock in extreme cases. Management is mainly supportive, including intravenous fluids and vasopressors if needed. Because of its irreversible binding, effects may persist for an extended period until new receptors are formed.
